Starpharma (ASX:SPL) reports DEP HER2-lutetium shows potent anticancer effect

Company News

by Rachael Jones

Starpharma (ASX:SPL) says its second radiopharmaceutical candidate, DEP HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regression, outperforming Herceptin labelled with lutetium, in a breast cancer model.

Worldwide, breast cancer is the most common cancer in women and the second most common cancer in the US.

Radiotheranostics is a rapidly developing area of cancer treatment and diagnosis, with deals and sales estimated to grow to $12–15 billion by 2030.

Recent deals include the acquisition of Endocyte by Novartis for US$2.1 billion and the acquisition of Sirtex by CDH Genetech for $1.9 billion.

Shares in Starpharma (ASX:SPL) are trading 1.1 per cent higher at $1.89.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.